A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)

Exclusion Criteria

• •Patient has allergies to materials necessary for endovascular repair (e.g. contrast media, anticoagulants or heparin, nitinol, polyester, gold, platinum-iridium)
• •Patient has systemic infection or suspected systemic infection
• •Patient has an infectious aneurysm
• •Patient has an inflammatory aneurysm
• •Patient has a ruptured aneurysm
• •Patient has a traumatic aneurysm
• •Patient has a symptomatic aneurysm
• •Patient has an aortic dissection
• •Patient has a congenital degenerative collagen disease or connective tissue disorder
• •Diameter of ostium of branch vessel to be treated \< 4 mm
• •Patient has thrombocytopenia (platelet count \< 150000/μl)
• •Patient has an eGFR \< 30 ml/min/1.73m2 before the intervention
• •Patient has untreated hyperthyroidism
• •Patient has a malignancy (progressive, stable or partial remission)
• •Patient had a myocardial infarction or cerebrovascular accident \< 3 months ago
• •Patient is planned to be treated with a chimney in the left subclavian artery
• •Patient has had a previous surgical repair of descending thoracic aorta
• •Patient will be treated or had been treated with a Nellix (Endologix) or Ovation (Endologix) or Altura (Lombard Medical) or Anaconda (Vascutek) stent graft
• •Patient is enrolled or plans to be enrolled in another clinical study
• •Patient is pregnant or breastfeeding or planning to become pregnant during the course of the study.
• •Patient has a life expectancy of less than 3 years